Luis Alvarez
AbbVie (NYSE:ABBV) has revealed plans to invest $195M in its manufacturing facility located in North Chicago, Illinois, to boost the production of active pharmaceutical ingredients domestically within the US.
This initiative follows AbbVie’s previous announcement to invest over $10B in the U.S. to expand manufacturing capabilities in the country.
The announcement comes at a time when major pharmaceutical companies, including Johnson & Johnson (JNJ) and Eli Lilly (LLY), have also committed to investing substantial amounts to expand their operations in the U.S. in the coming years, as President Donald Trump repeatedly threatened to impose tariffs on pharmaceuticals imported into the U.S.
“Over the next decade, AbbVie will expand production of API, drug product, peptides and medical devices in the U.S. to support future medical breakthroughs,” said Robert A. Michael, CEO of AbbVie.
The construction of the new North Chicago API facility will begin in fall 2025, with the site projected to be fully operational in 202, the company said.